Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Polycythemia Vera Market assumed to rise with a significant CAGR of 9.28% during the study period [2017-30]

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

25 Nov, 2020, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

LAS VEGAS, Nov. 25, 2020 /PRNewswire/ -- DelveInsight's Polycythemia Vera research report states that the market is expected to witness potential growth due to the launch of the drugs such as PTG-300, Givinostat, IMG-7289 and others that had shown positive therapeutic effects. However, there is a probability of failure of phase II emerging drugs in phase III, and strict pricing and reimbursement policies are expected to hinder the growth of the Polycythemia Vera Market.

The Polycythemia Vera Market Research report proffers insights on comprehension of the disease, historical and forecasted epidemiology; and Polycythemia Vera market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report also includes the current Polycythemia Vera treatment practice/algorithm, market drivers, market barriers and unmet medical needs to assess the underlying potential of the Polycythemia Vera market.

Key Findings of Polycythemia Vera Report

  • The hydroxyurea (alone or along with Phlebotomy), and aspirin constitute the first-line treatment among the current Polycythemia Vera treatment regimens. 
  • Besremi is an interferon-alpha 2b stimulant, which has already been approved in the European countries in 2019 and will enter the market as a first-line treatment, hence is expected to give stiff competition to hydroxyurea. It is expected to launch in the United States and Japan by 2021 and 2022, respectively. 
  • The second-line therapies fundamentally constitute Jakafi (Jakavi) and other therapies such as anagrelide and interferon-alpha. Jakafi is the only approved drug in the 7MM for second-line treatment. The Polycythemia Vera market size will undergo tough competition, wherein Jakafi is likely to maintain dominance in the hydroxyurea-refractory (second line) Polycythemia Vera market. 
  • Among the Polycythemia Vera emerging therapies for the second-line treatment, Protagonist Therapeutics, Italfarmaco, and Imago BioSciences are awaited to enter the treatment market during the forecast period [2020–30]. 
  • Interferon-α has been used in Polycythemia Vera and has shown notable activity in achieving hematologic responses and decreasing JAK2 V617F mutation allele burden. JAK inhibition has also been investigated and lately garnered regulatory approval. 

Have a question regarding how the trends will be impacting the Polycythemia Vera market, visit to download the sample: https://www.delveinsight.com/sample-request/polycythemia-vera-market 

Polycythemia Vera is a condition that is characterized by an increased number of red blood cells in the bloodstream and affected people may also have excess white blood cells and platelets. Most cases are not inherited and are acquired during a person's lifetime. 

Polycythemia Vera symptoms include double or blurred vision, blind spots, headaches, dizziness, and weakness. The most precarious sign is the chance for a thrombotic event that can cause a heart attack or stroke. 

Polycythemia Vera diagnosis is made by testing the blood for levels of a hormone called erythropoietin and assessing the blood for mutations in JAK2 or TET2. If mutations are not found in the red blood cells, and the doctors still suspect a diagnosis of Polycythemia Vera. In that case, a bone marrow biopsy may be done to examine for mutations in the hematopoietic blood cells that are located in the bone marrow.

The total prevalent population of Polycythemia Vera in the 7MM countries was found to be 283,442 in 2017. Most of the prevalent cases were reported in the United States with 157,290 cases in the same year. The males appear to have a predisposition to Polycythemia Vera which is why a higher percentage of symptomatic prevalence was observed in males as compared to females. 

The report provides a detailed historical and forecasted analysis of Polycythemia Vera Epidemiology segmented as:

  • Total Prevalent Population
  • Prevalence of Polycythemia Vera based on Symptoms
  • Gender-specific Symptomatic Prevalence 
  • Age-specific Symptomatic Prevalence 
  • Prevalence of Polycythemia Vera Based on Risk
  • Prevalence of Polycythemia Vera by Gene Mutation 

Polycythemia Vera Treatment Market 

Cytoreductive therapies have been used for older patients and those with a history of thrombosis. Hydroxyurea (HU) continues to be the first-line cytoreductive choice; although, up to one in four patients treated with HU over time will develop intolerance to HU and proceed for the second-line therapy. The patients who fail HU have a 5.6-fold increase in mortality and a 6.8-fold increased risk of transformation to myelofibrosis or AML; hence, alternative therapies are required for these patients. Interferon-α has been used in Polycythemia Vera and has shown potential activity in achieving hematologic responses and reducing JAK2 V617F mutation allele burden. JAK inhibition has also been investigated and lately garnered regulatory approval for this indication. 

Polycythemia Vera treatment has been classified as First-line and Second-line treatment. The hydroxyurea (alone or along with Phlebotomy), and Aspirin include the first-line treatment therapies. The second-line treatment, for intolerant to hydroxyurea patients, includes the only approved drug in the United States, Jakafi, and other therapies such as anagrelide, and interferon-alpha (such as PEG-Intron and Pegasys). 

Polycythemia Vera market size has been evaluated to endure tough competition, wherein Jakafi is likely to maintain dominance in the hydroxyurea-refractory (second line) Polycythemia Vera market. On the other hand, Besremi (by AOP Orphan Pharmaceuticals AG/PharmaEssentia), represents an even small risk, because the drug is being positioned in first-line treatment for Polycythemia Vera vs hydroxyurea. 

A few treatment options for Polycythemia Vera and complications associated with them offer an excellent opportunity for emerging therapies and the identification of new drug targets will boost the entry of novel therapies in the market.

Key players such as Italfarmaco [Givinostat; ITF2357], Imago BioSciences [Bomedemstat/IMG-7289], Protagonist Therapeutics [PTG-300], and others are working towards the development of the eligible candidate for the Polycythemia Vera treatment.

To know which emerging therapies will have an impact on Polycythemia Vera Market and how much market share will these drugs acquire, get access to the full report @ https://www.delveinsight.com/report-store/polycythemia-vera-market 

Scope of the Report

  • Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
  • Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
  • Markets Segmentation: By Geographies, By Therapies (Forecasted + Historical).
  • Companies Covered: Incyte Corporation, Novartis, AOP Orphan Pharmaceuticals AG, PharmaEssentia, Kartos Therapeutics, Italfarmaco, Protagonist Therapeutics, Promedior, Roche, Geron Corporation, Imago BioSciences, and several others.
  • Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis
  • Market trends, pipeline analysis across different stages of development (Phase III and Phase II), and market size by therapies.
  • Tools used such as SWOT analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.
  • Case Studies
  • KOL's Views
  • Analyst's View

Table of Contents

1.  Key Insights

2.  Executive Summary of Polycythemia Vera

3.  Polycythemia Vera Market Overview at a Glance

4.  Polycythemia Vera Disease Background and Overview

5.  Case Reports  

6.  Polycythemia Vera Epidemiology and Patient Population  

7.  United States Polycythemia Vera Epidemiology

8.  EU5 Polycythemia Vera Epidemiology

8.1.  KOL Insights

8.2.  Germany Epidemiology

8.3.  France Epidemiology

8.4.  Italy Epidemiology

8.5.  Spain Epidemiology

8.6.  United Kingdom Epidemiology

9.  Japan Polycythemia Vera Epidemiology

10.  Polycythemia Vera Treatment Algorithm, Current Treatment, and Medical Practices

11.  Unmet Needs

12.  Polycythemia Vera Marketed Products

12.1. Jakafi (Ruxolitinib): Incyte Corporation/Novartis

12.2. Besremi: AOP Orphan Pharmaceuticals AG/ PharmaEssentia

13.  Polycythemia Vera Emerging Therapies

13.1. KRT-232: Kartos Therapeutics

13.1. Givinostat: Italfarmaco

13.2. PTG-300: Protagonist Therapeutics

13.3. PRM-151: Promedior/Roche

13.4. Imetelstat (GRN163L): Geron Corporation

13.5. Bomedemstat (IMG-7289): Imago BioSciences

14.  Polycythemia Vera 7MM Market Analysis

15.  United States Polycythemia Vera Market Outlook

16.  EU-5 countries Polycythemia Vera Market Outlook

16.1. Germany Market Size

16.2. France Market Size

16.3. Italy Market Size

16.4. Spain Market Size

16.5. United Kingdom Market Size

17.  Japan Polycythemia Vera Market Outlook

17.1. Japan Market Size

18.  Polycythemia Vera Market Drivers

19.  Polycythemia Vera Market Barriers

20.  SWOT Analysis

21.  Reimbursement and Polycythemia Vera Market Access

22.  Appendix

23.  DelveInsight Capabilities

24.  Disclaimer

25.  About DelveInsight

Browse Detailed TOC, Tables, Figures, Emerging Drugs and Companies @ https://www.delveinsight.com/sample-request/polycythemia-vera-market 

Related Reports

  • Polycythemia Vera Epidemiology Forecast to 2030

DelveInsight's Polycythemia Vera Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Polycythemia Vera in 7MM.

  • Polycythemia Vera Pipeline Insights, 2020 

Polycythemia Vera Pipeline Insight, 2020 report by DelveInsight outlays detailed insights of present clinical development scenario and growth prospects.

  • Post-Polycythemia Vera Myelofibrosis Market Insight, Epidemiology and Market Forecast - 2030

Post-Polycythemia Vera Myelofibrosis Market Insights, Epidemiology, and Market Forecast report delivers an in-depth analysis of the historical and forecasted epidemiology and market trends. 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

Shruti Thakur
info@delveinsight.com
+91-9650213330
DelveInsight

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

DelveInsight's NADPH Oxidase (NOX)-Replacement Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a...

Frontotemporal Dementia Market Sees Rise in Precision Medicine and Gene Therapy Approaches | DelveInsight

Frontotemporal Dementia Market Sees Rise in Precision Medicine and Gene Therapy Approaches | DelveInsight

DelveInsight's Frontotemporal Dementia Market Insights report includes a comprehensive understanding of current treatment practices, frontotemporal...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.